JPH0351691B2 - - Google Patents
Info
- Publication number
- JPH0351691B2 JPH0351691B2 JP61141772A JP14177286A JPH0351691B2 JP H0351691 B2 JPH0351691 B2 JP H0351691B2 JP 61141772 A JP61141772 A JP 61141772A JP 14177286 A JP14177286 A JP 14177286A JP H0351691 B2 JPH0351691 B2 JP H0351691B2
- Authority
- JP
- Japan
- Prior art keywords
- nephritis
- kidney
- pronase
- chronic
- renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108010059712 Pronase Proteins 0.000 claims description 8
- 208000009928 nephrosis Diseases 0.000 claims description 7
- 231100001027 nephrosis Toxicity 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 11
- 201000008383 nephritis Diseases 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038381 Renal atrophy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000006059 curative reponse Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明はプロナーゼを有効成分とする腎ネフロ
ーゼ治療剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a therapeutic agent for renal nephrosis containing pronase as an active ingredient.
[従来の技術]
腎臓の疾患については既によく知られている。
腎臓の疾患として最も多い腎炎は、よく知られて
いるように、急性腎炎と慢性腎炎に区分され、さ
らに慢性腎炎の症状が進むと腎ネフローゼ(ネフ
ロゼ症侯群)、ついで腎不全に推移する。[Prior Art] Kidney diseases are already well known.
As is well known, nephritis, the most common kidney disease, is divided into acute nephritis and chronic nephritis, and as the symptoms of chronic nephritis progress further, the disease progresses to renal nephrosis (nephrotic syndrome) and then to renal failure.
急性腎炎は種々の原因、特に細菌原因等により
突発的に腎臓の組織が一時的に炎症を起こすもの
であり、通常抗生物質の投与による治療が行なわ
れており、自然治瘉することある。 Acute nephritis is a sudden and temporary inflammation of the kidney tissue due to various causes, especially bacterial causes, and is usually treated with antibiotics, and may resolve spontaneously.
一方、慢性腎炎では、腎臓組織の一時的炎症で
ある急性腎炎とは異なり、腎臓組織が不可逆的に
変化してしまい、糸球体の硝子化、線繊組織の増
殖、血管の狭窄、ネフロンの退化、腎臓の萎縮、
赤血球や白血球の大幅な減少等が生じており、い
わゆる組織の炎症としては捉えられていない。 On the other hand, in chronic nephritis, unlike acute nephritis, which is a temporary inflammation of the kidney tissue, the kidney tissue undergoes irreversible changes such as hyalinization of the glomeruli, proliferation of fibrillated tissue, narrowing of blood vessels, and degeneration of the nephron. , kidney atrophy,
There is a significant decrease in red blood cells and white blood cells, and this is not considered to be tissue inflammation.
このように急性腎炎と慢性腎炎とは病体像、組
織的変化において全く異なるものであり、それら
の疾患に対してそれぞれ異なる治療法が採用され
ている。さらに詳しくいえば急性腎炎に抗生物質
の投与により炎症の原因の治療が行なわれている
が、慢性腎炎には積極的な治療手段はなく、対症
療法がとられているのが現状である。 As described above, acute nephritis and chronic nephritis are completely different in their pathological features and histological changes, and different treatment methods are used for each of these diseases. More specifically, for acute nephritis, the cause of the inflammation is treated by administering antibiotics, but for chronic nephritis, there is currently no active treatment, and symptomatic treatment is currently being taken.
[発明が解決しようとする問題点]
従つて、急性腎炎の時期の炎症を治瘉すれば慢
性腎炎への移行を大幅に抑えられると考えられる
が、一旦慢性糸球体腎炎等の慢性腎炎に移行して
しまうと、もはや急性腎炎におけるような治療手
段はとれず、慢性腎炎の治瘉にもとより腎ネフロ
ーゼ、ついで腎機能不全への進行を止める積極的
な手立てはないものと考えられていた。[Problems to be Solved by the Invention] Therefore, if the inflammation during the stage of acute nephritis is cured, it is thought that the transition to chronic nephritis can be significantly suppressed, but once the transition to chronic nephritis such as chronic glomerulonephritis occurs. Once this occurs, it is no longer possible to take the same therapeutic measures as those for acute nephritis, and it was thought that there was no active measure to cure chronic nephritis or to stop the progression to renal nephrosis and then renal dysfunction.
[問題点を解決するための手段]
本発明者らは、蛋白分解酵素の研究を永年重ね
て来た結果、意外にも蛋白分解酵素のうちのプロ
ナーゼが慢性腎炎のみならず腎ネフローゼ治療剤
の治療に卓効を奏するという全く新たな事実を見
出し、本発明を完成するに至つた。[Means for Solving the Problems] As a result of many years of research into proteolytic enzymes, the present inventors found that pronase, a proteolytic enzyme, is surprisingly effective not only for chronic nephritis but also for renal nephrosis treatment. We have discovered a completely new fact that it is highly effective in treatment, and have completed the present invention.
なお、本出願の原出願(特願昭56−125002号:
特公平1−33085号)に記載された発明でいう慢
性腎炎とは蛋白尿排泄量が3.5g/日未満の腎炎
をいい、一方、本発明でいう腎ネフローゼとは蛋
白尿排泄量が3.5g/日以上のものをいう。 Please note that the original application for this application (Japanese Patent Application No. 125002/1982:
Chronic nephritis as used in the invention described in Japanese Patent Publication No. 1-33085) refers to nephritis in which the amount of proteinuria excreted is less than 3.5 g/day, while renal nephrosis as referred to in the present invention refers to nephritis in which the amount of proteinuria excreted is less than 3.5 g/day. / days or more.
[作用および実施例]
本発明の治療剤は通常の製造技術により、例え
ば錠剤、カプセル剤、散剤、顆粒剤等として経口
的に、注射剤、坐剤、軟膏剤等として非経口的に
投与できる。更に本剤は他の薬剤、例えば肝臓
薬、腎臓薬、抗生物質、免疫賦活剤、抗腫瘍剤な
どと併用できる。投与量は疾病度、投与法、剤型
等によつても異なるが、経口投与の場合は成人1
人につき1日当たり1〜50000mgにより、また腸
溶製剤としては、1〜1000mgにより、目的を達成
することができる。また投与量を酵素単位で表わ
した場合には、腸溶製剤にて1万〜50万チロジン
単位の経口投与により目的を達成することができ
る。とくに腸溶製剤とするのが好ましい。[Operations and Examples] The therapeutic agent of the present invention can be administered orally in the form of tablets, capsules, powders, granules, etc., or parenterally as injections, suppositories, ointments, etc., using conventional manufacturing techniques. . Furthermore, this drug can be used in combination with other drugs, such as liver drugs, kidney drugs, antibiotics, immunostimulants, and antitumor drugs. The dosage varies depending on the degree of disease, administration method, dosage form, etc., but in the case of oral administration,
The objective can be achieved with 1 to 50,000 mg per person per day, and as an enteric-coated preparation, with 1 to 1,000 mg. When the dosage is expressed in enzyme units, the purpose can be achieved by oral administration of 10,000 to 500,000 tyrosine units in an enteric preparation. In particular, enteric-coated preparations are preferred.
本発明の治療剤の特色は、吸収されたプロナー
ゼが障害部位の腎臓に極めて多量に移行し、かつ
障害部位の組織には浮腫の消褪、円形細胞の浸
潤、血管の新生、線維素の溶解、多糖類殊に酸性
多糖類の増加などが認められ、腎臓の慢性炎症像
即ち退行変成や異常増殖等に治瘉反応が惹起、促
進されていることが認められる。 The therapeutic agent of the present invention is characterized by a very large amount of absorbed pronase being transferred to the kidney at the site of injury, and in the tissue at the site of injury, there is disappearance of edema, infiltration of round cells, new blood vessels, and dissolution of fibrin. An increase in polysaccharides, particularly acidic polysaccharides, was observed, and it was observed that a curative reaction was induced and promoted in chronic inflammation of the kidney, such as degeneration and abnormal proliferation.
製剤例 1
プロナーゼ20g、乳糖40gを混合し、ヒドロキ
シプロピルメチルセルロース10gを加え顆粒に成
形したのち酢酸フタル酸セルロースを用い均等に
皮膜し、腸溶性顆粒とする。Formulation Example 1 20 g of pronase and 40 g of lactose are mixed, 10 g of hydroxypropyl methyl cellulose is added and the mixture is formed into granules, which are then evenly coated with cellulose acetate phthalate to form enteric-coated granules.
製剤例 2
製剤例1で得たプロナーゼ腸溶性顆粒をカプセ
ルに充填し、カプセル剤とする。Formulation Example 2 The pronase enteric-coated granules obtained in Formulation Example 1 are filled into capsules to prepare capsules.
臨床例
男性、48歳
診断名:ネフローゼ症侯群
主訴:食欲不振、無気力感
現病歴:半年前より食欲不振、無気力感を訴え
ていたが治療せず放置。健康診断にて蛋白
尿を指摘。Clinical case Male, 48 years old Diagnosis: Nephrotic syndrome Chief complaint: Anorexia, lethargy History of present illness: The patient had been complaining of anorexia and lethargy for six months, but was left untreated. Proteinuria was noted during a medical examination.
現症:体格 栄養中等度 顔面浮腫を呈す。
血圧163/92
尿検査:3.8g/日の多量の蛋白尿を示す。 Current symptoms: physique, moderate nutrition, facial edema.
Blood pressure: 163/92 Urinalysis: Shows a large amount of proteinuria of 3.8 g/day.
尿沈査:顆粒円柱、硝子様円柱、脂肪円柱が認
められる。とくに本症例には重屈折脂肪体
が認められた。 Urine sediment: Granular casts, hyaline casts, and fatty casts are observed. In particular, a heavily refractive fat pad was observed in this case.
大阪府立成人病センターに紹介、種々検査の上
ネフローゼ症侯群と診断。 The patient was referred to the Osaka Prefectural Adult Disease Center, and after various tests, he was diagnosed with nephrotic syndrome.
プロナーゼによる治療:
12月8日よりエンピナースPを1日6錠、毎食
後2錠ずつ内服した。 Treatment with pronase: From December 8th, the patient started taking 6 tablets of Empinase P per day, 2 tablets after each meal.
翌年1月14日:尿蛋白2.4g/日と減少。尿沈
査は変らず、全て円柱を認む。 January 14th of the following year: Urine protein decreased to 2.4g/day. There was no change in the urine sediment, and all casts were detected.
2月21日:尿蛋白1.2g/日と減少。 February 21st: Urine protein decreased to 1.2g/day.
尿沈査、全般的に減少するが猶全円柱を認む。 Urine sediment decreased overall, but casts were still observed.
3月30日:尿蛋白認めず。尿沈査消失。 March 30th: No protein in urine was detected. Urine sediment disappeared.
約110日でほぼ治瘉した。 The disease was almost cured in about 110 days.
[発明の効果]
本発明のプロナーゼを有効成分とする治療剤
は、従来有効な薬物療法がないとされていた腎ネ
フローゼの治療に卓抜した効果を奏する。[Effects of the Invention] The therapeutic agent of the present invention containing pronase as an active ingredient exhibits an outstanding effect on the treatment of renal nephrosis, for which no effective drug therapy has hitherto been considered.
Claims (1)
療剤。1. A therapeutic agent for renal nephrosis containing pronase as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61141772A JPS61293928A (en) | 1986-06-18 | 1986-06-18 | Remedy for renal nephrosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61141772A JPS61293928A (en) | 1986-06-18 | 1986-06-18 | Remedy for renal nephrosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56125002A Division JPS5826822A (en) | 1981-08-10 | 1981-08-10 | Preventing and pemedy for liver and kidney diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61293928A JPS61293928A (en) | 1986-12-24 |
JPH0351691B2 true JPH0351691B2 (en) | 1991-08-07 |
Family
ID=15299815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61141772A Granted JPS61293928A (en) | 1986-06-18 | 1986-06-18 | Remedy for renal nephrosis |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61293928A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826822A (en) * | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | Preventing and pemedy for liver and kidney diseases |
-
1986
- 1986-06-18 JP JP61141772A patent/JPS61293928A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826822A (en) * | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | Preventing and pemedy for liver and kidney diseases |
Also Published As
Publication number | Publication date |
---|---|
JPS61293928A (en) | 1986-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0133085B2 (en) | ||
JPH0552814B2 (en) | ||
AU2007280625B2 (en) | Use of escin | |
JP3721196B2 (en) | Use of magnesium-based products for the treatment or prevention of neoplastic and autoimmune diseases | |
JPH0156050B2 (en) | ||
JP4152641B2 (en) | Side effect reducing agent for thiazolidine derivatives | |
CN1169561C (en) | Medicine for treating diseases of rectum and anus | |
JPH0351691B2 (en) | ||
US20130039999A1 (en) | Use of clays for treating coeliac disease | |
CN114632128A (en) | Collateral-dredging and turbid-removing formula and using method thereof | |
JPH0213647B2 (en) | ||
JPS59225122A (en) | Remedy and improver for cancerous cachexia | |
Witkamp et al. | Efficacy and tolerability of multiple‐dose SDZ IMM 125 in patients with severe psoriasis | |
CN111000983A (en) | Medicinal use of new recombinant human interleukin-1 receptor antagonist | |
WO2003022292A1 (en) | Oral pharmaceutical formulation containing active carbon and use of the same | |
JPS608227A (en) | Antiallergic enhancer | |
JPS62215533A (en) | Preventive and remedy for intractable chronic disease | |
CN113332435B (en) | Sphingosine-1-phosphate 4 receptor agonist and application of sphingosine-1-phosphate 4 receptor agonist and Zhenwu decoction in preparation of medicine for treating chronic glomerulonephritis | |
RU2803967C1 (en) | Medical use of anemozide b4 in treatment of ulcers in oral cavity | |
PT1581227E (en) | A method for treating renal failure | |
KR100392225B1 (en) | Prodigiosin composition for the treatment of rheumatic arthritis | |
SU1284553A1 (en) | Method of treatment of chronic glomerulonephritis of nephrotic type | |
Shoji et al. | Drug eruption caused by nitrazepam in a patient with severe pustular psoriasis successfully treated with methotrexate and etretinate | |
JPH04971B2 (en) | ||
JP2006515011A (en) | HCV combination therapy |